stiripentol
Selected indexed studies
- Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first-line add-on therapies for seizures in Dravet syndrome: A network meta-analysis. (Epilepsia Open, 2024) [PMID:38427284]
- Stiripentol. (, 2012) [PMID:31644256]
- Stiripentol add-on therapy for drug-resistant focal epilepsy. (Cochrane Database Syst Rev, 2022) [PMID:36066395]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first-line add-on therapies for seizures in Dravet syndrome: A network meta-analysis. (2024) pubmed
- Stiripentol. (2012) pubmed
- Stiripentol add-on therapy for drug-resistant focal epilepsy. (2022) pubmed
- Stiripentol (Diacomit) for Dravet syndrome. (2021) pubmed
- Stiripentol: A Review in Dravet Syndrome. (2019) pubmed
- Stiripentol. (2006) pubmed
- Stiripentol add-on therapy for drug-resistant focal epilepsy. (2020) pubmed
- Efficacy and safety of stiripentol in the prevention and cessation of status epilepticus: A systematic review. (2024) pubmed
- Stiripentol in the Management of Epilepsy. (2017) pubmed
- Stiripentol identifies a therapeutic target to reduce oxaluria. (2020) pubmed